ICM
HALO icon

Invenomic Capital Management’s Halozyme HALO Stock Holding History

Invenomic Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77,793
Closed -$4.05M – 157
2025
Q2 		$4.05M Buy
+77,793
New +$4.43M 0.23% 110

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invenomic Capital Management's HALO Position: Q3 2025 in Review

Invenomic Capital Management sold out of Halozyme (HALO) in Q3 2025, closing a stake of 77,793 shares — an estimated $4.05M sold.

Invenomic Capital Management first reported a position in HALO in Q2 2025 and held it in 1 quarter. The position peaked at $4.05M in Q2 2025. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

  • Invenomic Capital Management reported no remaining Halozyme position as of Q3 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 77,793 Halozyme shares in Q3 2025, an estimated $4.05M.
  • Invenomic Capital Management first reported a position in Halozyme in Q2 2025 and held it in 1 quarter.
  • Invenomic Capital Management's Halozyme position peaked at $4.05M in Q2 2025.
  • 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Invenomic Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.